The cAMP response element modulator (CREM) regulates T<sub>H</sub>2 mediated inflammation

  • Verjans E
  • Ohl K
  • Reiss L
  • et al.
N/ACitations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

A characteristic feature of allergic diseases is the appearance of a subset of CD4+ cells known as TH2 cells, which is controlled by transcriptional and epigenetic mechanisms. We aimed to analyze the role of CREM, a known transcriptional activator of T cells, with regard to TH2 responses and allergic diseases in men and mice. Here we demonstrate that T cells of asthmatic children and PBMCs of adults with atopy express lower mRNA levels of the transcription factor CREM compared to cells from healthy controls. CREM deficiency in murine T cells results in enhanced TH2 effector cytokines in vitro and in vivo and CREM-/- mice demonstrate stronger airway hyperresponsiveness in an OVA-induced asthma model. Mechanistically, both direct CREM binding to the IL-4 and IL-13 promoter as well as a decreased IL-2 dependent STAT5 activation suppress the TH2 response. Accordingly, mice selectively overexpressing CREMα in T cells display decreased TH2 type cytokines in vivo and in vitro, and are protected in an asthma model. Thus, we provide evidence that CREM is a negative regulator of the TH2 response and determines the outcome of allergic asthma.

Cite

CITATION STYLE

APA

Verjans, E., Ohl, K., Reiss, L. K., van Wijk, F., Toncheva, A. A., Wiener, A., … Tenbrock, K. (2015). The cAMP response element modulator (CREM) regulates TH2 mediated inflammation. Oncotarget, 6(36). https://doi.org/10.18632/oncotarget.6041

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free